Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors
US10035800B2 · kind B2 · utility
3Cited by
0References
48Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 12, 2014 |
| Grant date | Jul 31, 2018 |
| Priority date | — |
| Expiry date | Mar 12, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/16
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y3, A1, A2, A3 and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.